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Phosphorylation-dependent ubiquitination and
degradation of the IFNAR1 chain of the type I inter-
feron (IFN) receptor is regulated by two different
pathways, one of which is ligand independent. We
report that this ligand-independent pathway is
activated by inducers of unfolded protein responses
(UPR), including viral infection, and that such
activation requires the endoplasmic reticulum-
resident protein kinase PERK. Upon viral infection,
activation of this pathway promotes phosphoryla-
tion-dependent ubiquitination and degradation of
IFNAR1, specifically inhibiting type I IFN signaling
and antiviral defenses. Knockin of an IFNAR1 mutant
insensitive to virus-induced turnover or conditional
knockout of PERK prevented IFNAR1 degradation,
whether UPR-induced or virus-induced, and restored
cellular responses to type I IFN and resistance to
viruses. These data suggest that specific activation
of the PERK component of UPR can favor viral repli-
cation. Interfering with PERK-dependent IFNAR1
degradationcould thereforecontribute to therapeutic
strategies against viral infections.
INTRODUCTION
Animal hosts defend themselves against infectious agents by
utilizing the mechanisms of innate and adaptive immunity.
Importantly, diverse pathways of innate immunity converge on
the induction of cytokines that belong to a family of type I inter-
ferons (IFN), including various types of IFNa and IFNb that play
a major role in host defenses against the viruses. Unlike IFNg,
which belongs to type II IFN group, all members of the type I
family act on cells via the same cognate receptor that consists72 Cell Host & Microbe 5, 72–83, January 22, 2009 ª2009 Elsevier Iof two subunits: IFNAR1 and IFNAR2c (reviewed in Pestka,
2000).
Dimerization of receptor chains in response to the ligands
results in the activation of Janus kinase (Jak) family members
Jak1 and Tyk2 that phosphorylate each other, the aforemen-
tioned receptor subunits, and the recruited signal transducers
and activators of transcription (Stat1 and Stat2) at specific tyro-
sines. Phosphorylated Stat proteins translocate to the nucleus,
bind to IFN-stimulated regulatory elements (ISRE), and activate
transcription of a large number of IFN-stimulated genes (ISGs;
reviewed in Stark et al., 1998). ISGs mediate a plethora of IFNa
effects that play key roles in antiviral defense (Brassard et al.,
2002; Katze et al., 2002), inhibition of cell proliferation (Brassard
et al., 2002; Kirkwood, 2002; Stark et al., 1998), and modulation
of immune responses (Biron, 2001; Brassard et al., 2002). The
ability of IFNa to evoke these outcomes makes it an attractive
therapeutic agent extensively used for treatment of patients
with neoplastic diseases (Kirkwood, 2002), chronic viral
infections (Brassard et al., 2002; Katze et al., 2002), and multiple
sclerosis (Karp et al., 2000).
Studies in cell culture revealed that antiviral effects of IFN
are best seen when it is added to cells prior to the infection
(Blalock and Baron, 1979; Pfeffer and Colamonici, 1991). While
decreased efficacy of IFN added to already-infected cells is
largely explained by insufficient time to transcribe and translate
ISG products (reviewed in Friedman and Sonnabend, 1970;
Pfeffer and Colamonici, 1991), additional mechanisms such as
a negative effect of virus on IFN action have been also postulated
(Lockart, 1963; Lockart and Horn, 1963). Indeed, many viruses
evolved to employ a multitude of specific mechanisms to protect
themselves against type I IFN. Thesemechanisms usually involve
a rapid synthesis of numerous virus type-specific proteins that
impede diverse elements of pathways converging on either IFN
production or IFN signaling (reviewed in Katze et al., 2002).
A need for the robust synthesis of viral polypeptides, however,
poses additional problems for the virus, as it challenges the
capacity of the host cell to properly fold and activate proteins.
Accumulation of suboptimally folded proteins in the ER of thenc.
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stress or the unfolded protein response (UPR) (Welihinda et al.,
1999). While the ER protein chaperone BiP is central to initiating
virtually all branches of the response, subsequent signaling
proceeds via a number of definedmechanisms that include other
transmembrane sensors, including ATF6, IRE1, and PKR-like ER
kinase (PERK). The activation of PERK and ensuing phosphory-
lation of eIF2a restricts translation to alleviate the load of
unfolded proteins (reviewed in Malhotra and Kaufman, 2007;
Ron and Walter, 2007). Viruses are known to both induce UPR
and produce the means of inhibiting these responses. The latter
is necessary in order to protect the host cells from ER stress-
mediated death, to enable translation of viral proteins, and to
continue virus production (He, 2006; Schroder and Kaufman,
2006; Wang and Weinman, 2006; Waris et al., 2002).
While investigating the mechanisms that govern proteolytic
degradation of type I IFN receptor, we found that IFNAR1
undergoes ligand-induced Tyk2 activity-dependent phosphory-
lation on specific Ser residues (Ser535 in humans and Ser526
in mice). This phosphorylation leads to the recruitment of
b-Trcp E3 ubiquitin ligase followed by IFNAR1 ubiquitination,
internalization, and lysosomal degradation (Kumar et al., 2007a,
2004, 2003; Marijanovic et al., 2006). Intriguingly, there is also
a ligand- andJak-independentpathway resulting inphosphoryla-
tion and turnover of IFNAR1 in cells that overexpressed this
receptor (Liu et al., 2008).
Here we present evidence that UPR triggers, including viral
infection, activate PERK to promote ligand- and Jak-indepen-
dent phosphorylation of IFNAR1 within its degron (a motif that
mediates proteolytic turnover), leading to IFNAR1 ubiquitination
and degradation as well as to suppression of type I IFN signaling.
We propose that this mechanism helps viruses to obviate the IFN
system and enable efficient replication. Our data also suggest
a potential for therapeutic targeting of PERK in treatment of viral
infections.
RESULTS
The UPR Induces PERK-Dependent Phosphorylation
of IFNAR1 Degron
Overexpressed IFNAR1 undergoes ligand- and Jak-indepen-
dent phosphorylation of the degradation motif (degron) followed
by ubiquitination and degradation of this receptor (Liu et al.,
2008). Increasing the amount of transfected IFNAR1 plasmid
led to a disproportionate increase in phospho-IFNAR1 signal
that cannot be explained solely by higher levels of total IFNAR1
expressed in these cells (Figure 1A). Furthermore, lysates from
these transfected cells displayed an elevated ability to phos-
phorylate bacterially produced GST-IFNAR1 protein on Ser535
(Figure 1B), indicating that forced expression of IFNAR1
activates a signal transduction pathway, inducing an unknown
protein kinase activity that phosphorylates IFNAR1 within its
degron.
Overexpression of secretory and transmembrane proteins
(such as IFNAR1) might overpower the ability of a cell to properly
fold these proteins in the ER and therefore initiate the UPR (We-
lihinda et al., 1999). Indeed, as seen in Figures S1 and S4, forced
expression of IFNAR1 induced the markers of the UPR, such as
BiP and ATF4, and promoted phosphorylation of eIF2a. SimilarCelresults, along with phosphorylation of endogenous IFNAR1 on
Ser535, were obtained upon overexpression of unrelated IFNg
receptor IFNGR1 (Figure S2). It appears that eIF2a phosphoryla-
tion was dependent on PERK, as is evident from experiments
using RNAi approach to knock down this kinase (Figures S3
and S4). Remarkably, thapsigargin (TG), a known inducer of
UPR, stimulated phosphorylation of endogenous IFNAR1 on
Ser535 in the absence of IFN (Figure 1C). Similar results were
obtained using other knownUPR stimuli, such as DTT (Figure S5)
and tunicamycin (data not shown).
We next investigated whether activity of Tyk2, which is
required for IFNAR1 phosphorylation in response to IFN (Liu
et al., 2008; Marijanovic et al., 2006), plays a role in the ligand-
independent pathway. To this end, we utilized derivatives of
human fibrosarcoma 2fTGH-derived cell lines originally sensitive
to type I IFN (John et al., 1991) but then having lost Tyk2 expres-
sion (Velazquez et al., 1992). These cells were reconstituted with
either wild-type (WT) Tyk2 or its catalytically inactive (KR) mutant
(Marijanovic et al., 2006). In line with the latter report, IFNa-
stimulated phosphorylation was inhibited in KR cells; however,
TG induced comparable levels of Ser535 phosphorylation of
IFNAR1 in both cell lines (Figure 1D). These data suggest that
UPR mediates phosphorylation of IFNAR1 in a ligand- and
Tyk2 kinase-independent manner.
We then investigatedwhich branch of UPRsignaling is involved
in regulating IFNAR1 phosphorylation. Mouse embryonic fibro-
blasts (MEFs) derived from PERK-null mice exhibited attenuated
IFNAR1 phosphorylation in response to TG, but not to murine
IFNb (Figure 1E). We further corroborated these data using the
MEFs from mice harboring a conditional knockout allele of
PERK (PERKfl/fl), where PERK is acutely excised upon trans-
duction with retrovirus encoding the Cre recombinase (Zhang
et al., 2002). The acute deletion of PERK inhibited IFNAR1
phosphorylation induced by TG without affecting IFN-triggered
phosphorylation (Figure 1F). Phosphorylation of IFNAR1 in
response to TG in human cells was not inhibited by either knock-
down of IRE1 or the expression of a dominant-negative mutant of
IRE1 (Figure S6 anddata not shown). Conversely, the knockdown
of PERK noticeably decreased the efficacy of IFNAR1 phosphor-
ylation induced by TG but not by IFNa in human cells (Figure S7).
Collectively, these data suggest that PERK is required for
IFNAR1 degron phosphorylation stimulated by UPR. Given that
activated PERK was not capable of phosphorylating IFNAR1
in vitro (data not shown), it is likely that one or more kinases
downstream of PERK are responsible for the direct phosphory-
lation of IFNAR1 degron.
The UPR Promotes IFNAR1 Ubiquitination
and Degradation by Inducing Degron Phosphorylation
in a Ligand- and Tyk2-Independent Manner
Phosphorylation within the IFNAR1 degron is expected to
promote ubiquitination of this receptor and its degradation in
the lysosome (Kumar et al., 2004, 2003; Marijanovic et al.,
2006). Indeed, treatment of cells with TG decreased the levels
of IFNAR1 in human cells within 2 hr, even in the absence of
IFN. This decrease was prevented by pretreating cells with
methylamine HCl (MA), an inhibitor of the lysosomal pathway
(Figure 2A). Furthermore, TG treatment induced ubiquitination
of IFNAR1 and downregulated this receptor in humanl Host & Microbe 5, 72–83, January 22, 2009 ª2009 Elsevier Inc. 73
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Virus- and UPR-Mediated IFNAR1 DegradationFigure 1. ERStress Induces IFNAR1Ser535Kinase Activity andPromotes Phosphorylation of IFNAR1within Its DestructionMotif in aManner
that Does Not Require Tyk2 Activity but Relies on Activity of PERK
(A) Lysates from KR-2 cells (lacking catalytic activity of Tyk2) transfected with FLAG-IFNAR1 plasmid (0–3.0 mg) were subjected to immunoprecipitation (IP) using
anti-FLAG antibody followed by immunoblotting (IB) using the indicated antibodies. Relative intensity of bands in IB using anti-phospho-S535 (black squares),
IFNAR1 (R1, gray circles), or FLAG (black circles) was quantified and plotted on the right.
(B) Lysates from KR-2 cells transfected with FLAG-IFNAR1 (1.5–3.0 mg) or empty vector were used as a source of kinase activity in an in vitro kinase assay using
GST-IFNAR1 as a substrate. The reactions were analyzed by IB using anti-phospho-S535 antibody (upper panels; both shorter and longer exposures are shown)
and by Ponceau staining to detect the substrate levels (middle). Levels of FLAG-IFNAR1 in the cell lysates were analyzed by IB using anti-FLAG antibody (lower).
(C) 293T cells were treated with thapsigargin (TG, 1 mM) for 30min. Endogenous IFNAR1 was immunoprecipitated and analyzed by IB using indicated antibodies.
Aliquots of the whole cell lysates were analyzed for levels of phospho- and total eIF2a.
(D) Cells harboring the WT Tyk2 (WT-5) or the kinase dead Tyk2 (KR-2) were treated with IFNa (1000 IU/ml) or TG at indicated concentrations for 30 min.
Endogenous IFNAR1 was analyzed by IP-IB as in (C).
(E) WT or PERK/ MEFs were treated with TG (1 mM) or murine IFNb (1000 IU/ml) for 30 min. Mouse endogenous IFNAR1 was analyzed for its phosphorylation
and levels using the indicated antibodies.
(F) MEFs from PERKfl/fl mice that received an empty vector (Mock) or vector for expression of Cre recombinase (Cre) were treated and analyzed as in (E). Whole
cell lysates from these cells were also analyzed by IB using the indicated antibodies.fibrosarcoma cells that express eitherWT or KR Tyk2 (Figure 2B),
as well as in 293T cells (Figure S8). Ligand-independent stimula-
tion of IFNAR1 ubiquitination by TG was also seen in IFNAR1-
null MEFs reconstituted with IFNAR1WT, but not in MEFs that
express IFNAR1SA mutant lacking the degron phosphorylation
site (Figure S9). These results indicate that induction of the
UPR promotes phosphorylation-dependent ubiquitination of
IFNAR1 and downregulates its levels in a manner independent
of Tyk2 and of exogenous IFN.
Treatment of cells with TG decreased the half-life of IFNAR1,
but not of an unrelated short-lived protein, c-Jun, in 293T cells
treated with cycloheximide to inhibit translation (Figure 2C).74 Cell Host & Microbe 5, 72–83, January 22, 2009 ª2009 Elsevier InKnockdown of PERK decreased the ubiquitination of exoge-
nously overexpressed IFNAR1 and noticeably increased its level
in human cells (Figure 2D). Similarly, TG-induced ubiquitination
of IFNAR1 was alleviated in PERK-deficient mouse cells (data
not shown). In addition, acute Cre-mediated ablation of PERK
slowed down UPR-induced turnover of both endogenous
(Figure 2E) and exogenously expressed mouse IFNAR1
(Figure 2F). In contrast to that, degradation of another b-Trcp
substrate, phosphorylated b-catenin, was not affected under
these conditions (Figure 2E). Collectively, these data suggest
that UPR promotes ubiquitination and degradation of IFNAR1
in a PERK-dependent manner.c.
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Virus- and UPR-Mediated IFNAR1 DegradationFigure 2. ER Stress Promotes IFNAR1 Ubiquitination and Degradation in a Ligand/Jak-Independent Manner
(A) Levels of endogenous IFNAR1 in 293T cells pretreated or not with methylamine HCl (MA, 20 mM) for 1 hr and then treated with TG (1 mM) for indicated time
were analyzed by IP-IB. Levels of b-actin in whole cell lysates are also shown.
(B) Cells harboring the WT Tyk2 (WT-5) or the kinase dead Tyk2 (KR-2) were treated with TG as indicated, and ubiquitination and levels of endogenous IFNAR1
were analyzed by IP-IB. Aliquots of whole cell lysates were also analyzed by IB using anti-b-actin antibody (lower).
(C) 293T cells were pretreated or not with MA for 1 hr and then treated with cycloheximide (Chx, 50 mg/ml) alone or together with TG (1 mM) for indicated times.
Levels of endogenous IFNAR1 were analyzed by IP-IB. Levels of c-Jun and b-actin in whole cell lysates were also determined by IB using indicated antibodies.
(D) Ubiquitination of FLAG-tagged IFNAR1 coexpressedwith the indicated shRNA constructs in 293T cells was analyzed by IP using anti-FLAG antibody followed
by IB using anti-ubiquitin and anti-Flag antibodies as indicated. Aliquots of whole cell lysates were also analyzed by IB using anti-b-actin antibody (lower).
(E) PERKfl/fl MEFs that either underwent acute deletion of PERK (Cre) or not (Mock) were treated with 1 mM of TG (together with Chx, 10 mg/ml) for 45 min as
indicated. Endogenous mouse IFNAR1 was analyzed by IP-IB using the indicated antibodies. Whole cell lysates were also subjected to IB analysis to determine
levels of phosphorylated b-catenin and eIF2a, as well as total levels of PERK and eIF2a, using respective antibodies. Ig, heavy chain immunoglobulins; NS,
nonspecific band.
(F) Mouse FLAG-IFNAR1 expressed in PERKfl/fl MEFs that either underwent acute deletion of PERK (Cre) or not (Mock) were analyzed by IB using anti-FLAG
antibody. Levels of PERK are shown in lower panel. NS, nonspecific band that serves as a loading control.We next sought to investigate whether UPR-stimulated
IFNAR1 degradation is mediated via phosphorylation of Ser resi-
dues within the IFNAR1 degron. To this end, we generated
mouse embryonic stem (ES) cells that harbor one mutant
IFNAR1S526A allele introduced via a homologous recombination
approach (Figures 3A and 3B). These cells were grown as
embryoid bodies (EBs) and differentiated into fibroblast-like cells
for analysis. Although treatment with TG induced a comparable
level of eIF2a phosphorylation in both WT and S526A knockin
cells, the latter displayed a grossly reduced phosphorylation of
IFNAR1 on Ser526 (Figure 3C). Furthermore, TG-stimulated
degradation of IFNAR1 was clearly inhibited in the S526A
knockin cells (Figure 3D). These data indicate that UPR-induced
acceleration of proteolytic turnover of IFNAR1 depends on its
phosphorylation within the specific degron.
VSV and HCV Accelerate the Degradation of IFNAR1 via
Induction of PERK-Dependent IFNAR1 Degron
Phosphorylation
While IFNa/b play a major role in the defense against viruses,
pretreatment of as-yet-uninfected cells with these cytokines is
often required to obtain the protective effect. Numerous viruses,Celincluding hepatitis C virus (HCV) (Ciccaglione et al., 2007; Wang
andWeinman, 2006; Zheng et al., 2005), are known to massively
express their proteins and cause ER stress. Therefore, we
sought to investigate whether virus-induced UPR might also
affect IFNAR1 phosphorylation and stability that may also lead
to inhibiting IFN responsiveness of already-infected cells.
Infection of 2fTGH human fibrosarcoma cells with vesicular
stomatitis virus (VSV) induced the expression of UPR markers
(Figure S10). Intriguingly, this infection also stimulated IFNAR1
phosphorylation on Ser535 and decreased total levels of IFNAR1
(Figure S11). Similar results and an increase in the extent of
IFNAR1 ubiquitination were observed in the KR-derivative cell
line (Figure 4A), indicating that VSV infection promotes IFNAR1
phosphorylation, ubiquitination, and degradation in a Tyk2-
independent manner. Furthermore, given that Tyk2 activity is
essential for IFN-induced IFNAR1 phosphorylation (Marijanovic
et al., 2006), this result suggests that the effects of VSV on
IFNAR1 downregulation could not be attributed solely to induc-
tion of endogenous IFN.
Infection with HCV promotes the ER stress (Tardif et al., 2005;
Waris et al., 2002) that is robustly stimulated by the synthesis of
structural proteins (Ciccaglione et al., 2005) known to reside inl Host & Microbe 5, 72–83, January 22, 2009 ª2009 Elsevier Inc. 75
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Huh7 cells, total levels of endogenous IFNAR1 were dramatically
downregulatedby stable transfection of a completeHCVgenome
(Figure 4B). When the levels of IFNAR1 taken into immunoprecip-
itation were normalized to yield comparable total levels of
IFNAR1, a robust phosphorylation of IFNAR1 degron was de-
tected in Huh7 cells expressing the complete HCV genome (Fig-
ure 4C). Thus, it is plausible that the effects of viral infection/
expression of viral proteins on IFNAR1 levels could be mediated
via IFNAR1 degron phosphorylation and ensuing degradation.
Figure 3. ER Stress Promotes IFNAR1
Degradation in a Manner Depending on
IFNAR1 Phosphorylation within Its Phos-
pho-Degron
(A) Targeting strategy to generate an S526A allele
in mouse ES cells (C57/BL6). Position of mutated
Ser residue, resistance markers, and loxP sites,
as well as restriction sites and the probe used for
Southern analysis, are shown.
(B) Southern analysis of several selected ES
clones that underwent homologous recombina-
tion (marked by an asterisk) was performed on
genomic DNA digested with KpnI. Correct target-
ing yielded a 10.6 kb band in clones 106 and 252
(besides the 8.5 kb band indicative of the WT
allele).
(C) EBs derived from the WT (WT/WT) or the
mutant (S526A/WT) ES were trypsinized, and the
EB-derived cells were propagated on gelatinized
plates. Cells were pretreated or not with MA
(20 mM, 1 hr) and then treated with TG (1 mM,
15 min) as indicated. Endogenous mouse IFNAR1
was immunoprecipitated and analyzed by IB using
the indicated antibodies. Phosphorylation of eIF2a
and levels of PKRwere also determined in aliquots
of whole cell lysates by IB.
(D) EB-derived cells were treated with TG (1 mM)
for indicated times and analyzed for total levels
of endogenous IFNAR1 (by IP-IB). Levels of
eIF2a phosphorylation and total b-catenin were
shown as stress and loading controls, respec-
tively.
Figure 4. Viral Infection Promotes Phosphorylation-
Dependent Ubiquitination and Downregulation of
IFNAR1 in a Tyk2-Independent and S535/526-Depen-
dent Manner
(A) Ubiquitination, phosphorylation, and total levels of endog-
enous IFNAR1 from KR-2 cells infected with VSV (for 16, 18,
and 20 hr) were analyzed by IP using anti-IFNAR1 antibody
followed by IB using the indicated antibodies. Viral protein
accumulation is shown by the levels of VSV-M.
(B) Levels of endogenous IFNAR1 in the lysates from Huh7
cells (parental or harboring either a full-length or subgenomic
HCV) were analyzed by IP-IB. Levels of b-actin in the lysates
aliquots are also shown.
(C) Endogenous IFNAR1 proteins were immunopurified from
the indicated cells as in (B) and loaded onto the gel to yield
comparable levels of total IFNAR1 (lower). Phosphorylation
of IFNAR1 was then analyzed by IB using indicated antibody
(upper).
(D) MEFs from IFNAR1/mice were stably reconstituted with
murine FLAG-IFNAR1 (either WT or S526A mutant) and then
infected with VSV (for 16–18 hr). Levels of IFNAR1, VSV-M,
and b-actin were analyzed by IB.
(E) EB-derived cells of WT (WT/WT) or mutant (S526A/WT)
genotype were infected or not with VSV for 12 hr and lysed.
Under these conditions, levels of VSV-M become saturated
at 10 hr postinfection (data not shown). Levels of endogenous
mouse IFNAR1 were determined by IP-IB. Levels of b-actin
and VSV-M in the lysates were also determined.
76 Cell Host & Microbe 5, 72–83, January 22, 2009 ª2009 Elsevier Inc.
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(A) Phosphorylation and levels of endogenous IFNAR1 in 2fTGH cells that received indicated shRNA constructs and were then infected with VSV (for 16, 18, and
20 hr) were analyzed by IP-IB using the indicated antibodies. Aliquots of IP supernatants were used for analysis of VSV-M, p-eIF2a, and eIF2a levels by IB.
(B) Control or PERK-depleted 2fTGH cells as in (A) were infected with VSV (for 17 hr) and then treated with Chx (1 or 10 mg/ml for 1.5 hr). Total levels of IFNAR1
were determined by IP-IB.
(C) Levels of cell surface IFNAR1 analyzed by FACS using monoclonal anti-mIFNAR1 antibody in MEFs from PERKfl/fl mice (transduced with either empty vector
[Mock] or construct for expression of Cre) were either left untreated (black line), infected with VSV (for 17 hr, red line), or treated with TG (1 mM for 4hr, green line).
Blue line represents the isotype Ig control.
(D) Levels of IFNAR1 and actin in Huh7 cells harboring the full-length or subgenomic HCV that were cotransfected with FLAG-IFNAR1 and indicated shRNA
constructs were analyzed using indicated antibodies.Indeed, while VSV infection dramatically downregulated
murine FLAG-tagged IFNAR1 (re-expressed in MEFs from
IFNAR1-null mice), a noticeably lesser effect was observed on
mutant IFNAR1S526A (Figure 4D). This result was further corrob-
orated in IFNAR1S526A knockin cells that were more resistant in
decreasing IFNAR1 levels in response to VSV (Figure 4E). These
data indicate that phosphorylation of IFNAR1 degron is impli-
cated in the receptor downregulation stimulated by virus.
Knockdown of PERK in human 2fTGH cells (Figure S12) atten-
uated degron phosphorylation and downregulation of IFNAR1 in
cells infected with VSV (Figure 5A). Similarly, downregulation of
IFNAR1 in VSV-infected 2fTGH cells was prevented by shRNA
against PERK, but not by a number of irrelevant shRNAs or
shRNA against IRE1 (Figure S13). Accordingly, a much lesser
extent of degradation of IFNAR1 promoted by VSV infection
(measured in cycloheximide-treated cells) was detected in
PERK knockdown cells (Figure 5B). Furthermore, Cre-mediated
ablation of PERK decreased the extent of downregulation of cell
surface IFNAR1 levels in response to either TG treatment or VSV
infection (Figure 5C). In addition, knockdown of PERK partially
rescued a decrease in IFNAR1 observed in Huh7 cells express-
ing the complete HCV genome (Figure 5D). These data suggest
that viral infection and expression of structural viral proteins
promote downregulation and degradation of IFNAR1 via
a PERK-dependent signaling.CelVSV and HCV Attenuate Cellular Responses
to Type I IFN via PERK-Dependent Phosphorylation
and Downregulation of IFNAR1
Attenuated antiviral defense observed in cells from IFNAR1+/
mice suggests that levels of IFNAR1 are important for type I
IFN signaling (Hwang et al., 1995; Muller et al., 1994). Therefore,
IFNAR1 downregulation triggered by UPR activation is expected
to inhibit cellular responses to IFNa/b. Indeed, either infection of
cells with VSV (Figure 6A) or pretreatment of cells with TG
(Figure S14) noticeably decreased tyrosine phosphorylation of
Stat1 induced by IFNa in human cells. Much lesser inhibition
was seen in cells treated with IFNg that utilizes an entirely
different receptor (Pestka, 2000; Schreiber and Farrar, 1993)
but still requires IFNAR1 for maximal signaling (Takaoka et al.,
2000).
The expression of the complete HCV genome in Huh7 cells
dramatically inhibited Stat1 phosphorylation induced by IFNa
while IFNg signaling was only modestly affected (Luquin et al.,
2007 and Figure S15). Remarkably, expression of IFNAR1
proteins in these cells partially rescued type I IFN signaling;
this effect was especially pronounced when a stabilized
IFNAR1S535A mutant (that lacks Ser responsible for UPR-driven
degradation; Figure 4) was used (Figure 6B). Similarly, a lesser
inhibitory effect of VSV infection on type I (but not type II) IFN
signaling was observed in cells derived from the IFNAR1S526Al Host & Microbe 5, 72–83, January 22, 2009 ª2009 Elsevier Inc. 77
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Virus- and UPR-Mediated IFNAR1 DegradationFigure 6. Viral Infection Inhibits Type I IFN Signaling via Accelerating Ser526 Phosphorylation-Dependent Degradation of IFNAR1
(A) 2fTGH cells infected or not with VSV (for 20 hr) were treated with 50 IU/ml of IFNa or IFNg for 30 min. Phosphorylation of Stat1 and total levels of Stat1, actin,
and VSV-M were analyzed by IB.
(B) Indicated Huh7 cell line derivatives were cotransfected with FLAG-STAT1 and either empty vector (pcDNA3) or FLAG-IFNAR1 (WT or S535A), as indicated.
Lysates from these cells treated or not with IFNa (50 IU/ml) were immunoprecipitated using anti-FLAG antibody, and these reactions were analyzed by IB using
the indicated antibodies.
(C) EB-derived cells of wild-type (WT/WT) or mutant (S526A/WT) genotype were infectedwith VSV (for 12 hr) and then treatedwith murine IFNb (100 IU/ml) or IFNg
(5 ng/ml) for 30 min. Phosphorylation of Stat1 and total levels of Stat1 and actin were analyzed by IB.
(D) Titer of VSV produced in EB-derived cells 14 hr after infection (an incubation of cells with VSV at MOI 1.0 for 1 hr) is depicted. The effect of IFNb (20 IU/ml)
added either 16 hr prior to the infection (pretreat) or immediately after infection (co-add) was determined. Data shown (the mean ± SD) are representative of two
independent experiments (each in triplicate). Asterisk denotes p < 0.01 in comparison with untreated cells.knockin ES cells (Figure 6C). These results indicate that ER
stress and viral infection inhibit type I IFN signaling via phosphor-
ylation-dependent downregulation of IFNAR1.
We then sought to investigate the role of this regulation in anti-
viral defense. While pretreatment of WT cells with IFNb exhibited
an antiviral effect, this cytokine was inefficient when added
immediately after the virus. However, under the latter conditions,
cells that harbored the knocked in IFNAR1S526A mutant were
capable of utilizing IFNb to significantly reduce VSV propagation
(Figure 6D). These results indicate that viruses at least tempo-
rarily benefit from the induced phosphorylation-dependent
degradation of IFNAR1 and the ensuing suppression of the
antiviral defenses.
This hypothesis was further corroborated when we investi-
gated the role of PERK in type I IFN-induced signaling and anti-
viral defense. Either knockdown of PERK in human cells (using
RNAi approach) or acute genetic ablation of PERK in MEFs
(using Cre expression) led to the rescue of Stat1 phosphorylation
in response to type I IFNs (Figures 7A and 7B). Judging from
expression of the M protein of VSV (VSV-M), PERK-deficient
cells contained fewer viruses; however, even when exposed to
a 5-fold higher viral titer to achieve a comparable expression
of VSV-M, these cells remained competent in IFNb-induced78 Cell Host & Microbe 5, 72–83, January 22, 2009 ª2009 Elsevieractivation of Stat1 (Figure 7C). Such protection was not seen in
infected MEFs lacking a related kinase, PKR (Figure S16).
Specific role of PERK was further corroborated by data demon-
strating that PERK knockdown in Huh7 cells expressing
complete HCV genome also restored the ability of these cells
to conduct type I IFN signaling (Figure 7D). These data suggest
that PERK plays an important role in virus-mediated inhibition
of cellular responses to IFNa/b.
PERK knockdown in human cells increased their overall resis-
tance to VSV and promoted the ability of cells to utilize IFNa
added after the virus to significantly suppress the replication of
VSV in these cells (Figure 7E). This finding is counterintuitive,
as both the previous report (Baltzis et al., 2004) and our own
data (Figure S17) indicated that MEFs derived from conventional
PERK knockout embryos are somewhat more sensitive to viral
infection. Accordingly, conventional PERK-null MEFs displayed
a somewhat reduced response to IFN, as evident from analysis
of the ISRE-driven luciferase reporter (Figure S18). However,
re-expression of PERK in these cells did not stimulate either
IFN responses or antiviral defenses (Figures S17 and S18),
suggesting that conventional PERK-null cells underwent an
additional alteration to decrease IFN signaling. One cannot rule
out that this alteration was to compensate for an impaired abilityInc.
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Virus- and UPR-Mediated IFNAR1 DegradationFigure 7. Role of PERK in Virus-Induced Suppression of Type I IFN Signaling
(A) Control or PERK-depleted derivatives of 2fTGH cells were infected with VSV (for 20 hr) and then treated with IFNa or IFNg (50 IU/ml for 30 min). Phosphor-
ylation and total levels of Stat1 and eIF2a were analyzed by IB.
(B)MEFs fromPERKfl/flmice transducedwith either empty vector (Mock) or construct for expression of Crewere infected with VSV (for 20 hr) and then treatedwith
IFNb (100 IU/ml) or IFNg (5 ng/ml) for 30 min. Phosphorylation and total levels of Stat1 were analyzed by IB.
(C) MEFs from PERKfl/fl mice transduced as indicated were infected with VSV at MOI 0.1 (+) or 0.5 (++) for 20 hr and then treated with IFNb for 30 min. IB analyses
using indicated antibodies are shown.
(D) Indicated derivatives of Huh7 cells were cotransfected with indicated shRNA constructs and FLAG-STAT1 and treated with IFNa (50 IU/ml) for 30 min. Stat1
proteins were immunoprecipitated using anti-FLAG antibody and analyzed by IB using anti-phospho-Stat1 and anti-Stat1 antibody.
(E) Titer of VSV produced in control or PERK-depleted derivatives of 2fTGH cells 14 hr after infection (an incubation of cells with VSV atMOI 1.0 for 1 hr). The effect
of IFNa (20 IU/ml) added either 16 hr prior to the infection (pretreat) or immediately after infection (co-add) was determined. Data shown (the mean ± SD) are
representative of two independent experiments (each in triplicate). Asterisk denotes p < 0.01 in comparison with untreated cells.
(F) MEFs from PERKfl/fl mice transduced as indicated were infected with VSV (MOI 1.0). Twenty hours after infection, viral titer in the culture supernatant was
determined. Values represent the mean ± SD of three independent experiments, each performed in triplicate. VSV-M protein levels analyzed by IB in cell lysates
are also shown in the inset.
(G) 2fTGH and isogenic IFNAR2-deficient U5a cells were transduced with indicated shRNA constructs and then infected with VSV (MOI 1.0) for 18–20 hr. Levels
of VSV-M, ISG15, and b-actin were determined by IB. In a parallel experiment, these cells were treated with TG (1 mM for 30 min) and analyzed for PERK levels by
IP-IB (lower).to downregulate IFNAR1 via the ligand-independent pathway
that has been previously shown to impede cell growth (Liu
et al., 2008). Conversely, a compensatory pathway that rescued
growth of cells overexpressing a dominant-negative mutant of
PERK has been also reported (Yamaguchi et al., 2008). There-
fore, to investigate the role of PERK in murine cells, we turnedCelto a model of Cre-mediated acute ablation of PERK in MEFs
from PERKfl/fl mice that did not display defects in ISRE-
dependent transcription (data not shown).
Remarkably, expression of Cre rendered these MEFs more
resistant to VSV in the absence of added IFN (as seen from
a decreased viral titer and expression of VSV-M, Figure 7F).l Host & Microbe 5, 72–83, January 22, 2009 ª2009 Elsevier Inc. 79
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sion of IFN-stimulated protein ISG15 and becamemore resistant
to VSV infection (as judged by the lower levels of VSV-M protein,
Figure 7G). These effects of PERK loss of function appeared to
largely depend on the IFN pathway, as much lesser changes
were observed in isogenic U5a cells lacking IFNAR2. This
conclusion was also supported by the fact that expression of
VSV-M in infected PERK knockdown cells was noticeably
increased by treatment with anti-IFNa/b antibodies (Figure S19).
In all, these results suggest that activation of PERK is utilized by
VSV to inhibit cellular responses to IFN and antiviral defenses;
this mechanism at least partially relies on UPR-induced, PERK-
dependent downregulation of IFN receptor.
DISCUSSION
Ligand-stimulated, Jak-dependent ubiquitination and degrada-
tion of type I IFN receptor plays a key role in the negative regu-
lation of IFNa/b signaling (Kumar et al., 2003). However, recent
evidence suggested the existence of a ligand- and Jak-indepen-
dent pathway that controls stability of IFNAR1 in a phosphoryla-
tion-dependent manner. The importance of the latter pathway
remained unclear, as it was largely observed under the condi-
tions of IFNAR1 overexpression (Liu et al., 2008). Here, we report
that this pathway is triggered by activation of the ER stress in
a manner that requires function of PERK. Among the evidence
supporting this conclusion are the following: (1) stimuli that
cause UPR induce Ser phosphorylation within the IFNAR1
degron and promote IFNAR1 ubiquitination and degradation in
cells that were not treated with IFN and in a Tyk2-indepenent
manner; (2) UPR-induced ubiquitination and degradation of
IFNAR1 is inhibited in cells harboring knocked in IFNAR1 mutant
lacking phospho-acceptor site in its degron; and (3) phosphory-
lation, ubiquitination, and degradation of IFNAR1 induced by
UPR are attenuated in PERK-deficient cells.
Furthermore, we found that this pathway, which leads to
accelerated degradation of IFNAR1, is utilized by some viruses
(including VSV andHCV). Future studies are necessary to identify
other viral species that might inhibit IFN signaling by downregu-
lating the receptor. Infection by VSV and expression of HCV
genome led to downregulation of IFNAR1 and to inhibition of
signaling and antiviral effects induced by type I IFN. These
effects are at least partially impaired in cells that either lack
PERK or contain phospho-degron mutant of IFNAR1 that is
insensitive to PERK-induced phosphorylation and degradation.
Given that many human and animal virus infections are known
to induce the UPR (He, 2006; Schroder and Kaufman, 2006;
Wang and Weinman, 2006; Waris et al., 2002), we propose that
some rapidly propagating viruses might generally employ the
ligand-independent degradation of IFNAR1 to suppress antiviral
defenses in cells that have not yet been exposed to IFN. It is also
tempting to speculate that this mechanism might play a role in
pathogenesis of some viral infectious diseases.
ER stress response has evolved to help the cells to deal with
protein overload, which, among other scenarios, also occurs
during acute viral infections. According to a current paradigm,
being a cellular protective mechanism, UPR as a whole should
help to limit viral infection (He, 2006). Our data, however, strongly
suggest that specific activation of the PERK branch of UPR80 Cell Host & Microbe 5, 72–83, January 22, 2009 ª2009 Elseviercould instead favor viral replication via IFNAR1 degradation
and suppression of IFN responses. Such an observation is not
entirely unexpected, considering that one major consequence
of PERK activation is an inhibition of translation through eIF2a
phosphorylation, which, in cells infected by viruses, can also
be carried out by PKR. It is plausible that this redundancy in
means of translational inhibition might permit a sustained stimu-
lation of PERK to negate IFN signaling and promote the infection.
Intriguingly, while viruses often impede PKR-dependent phos-
phorylation of eIF2a (Bergmann et al., 2000; Gale et al., 1997;
Gil et al., 2006; Langland and Jacobs, 2002), the examples of
perturbation of PERK activation per se are rare (He, 2006).
During the initial rounds of infection, ligand-independent
degradation of IFNAR1 could be of particular importance for
a virus that has penetrated a naive cell and started to produce
massive amounts of viral proteins to prepare for replication. At
this time, activation of ER-triggered IFNAR1 degron phosphory-
lation and ensuing degradation is expected to dramatically
reduce the sensitivity of an infected cell to either exogenous or
endogenously produced and secreted IFNa/b (as seen in Figures
6 and 7). Such alterations should benefit the offending virus in at
least two ways. First, accelerated degradation of IFNAR1 will
prevent an efficient induction of expression and activities of
diverse antiviral proteins (including 20-50 oligoadenylate synthe-
tases, the Mx proteins, PKR, and the double-stranded-
RNA-specific adenosine deaminase) that are known to suppress
various steps of viral replication (reviewed in Guidotti and Chis-
ari, 2001). Second, and perhaps equally important, downregula-
tion of IFNAR1 protects the host cell from the proapoptotic
effects of IFN (Chawla-Sarkar et al., 2002a, 2002b) and therefore
affords the virus a sufficient time for completion of its infectious
cycle. Regardless of which of these pathways are more relevant
for each specific virus, our data strongly suggest that UPR-medi-
ated downregulation of type I IFN receptor and its signaling are
important for unabated completion of initial rounds of infection
when the majority of target host cells are yet to encounter IFN.
Although such a mechanism should briefly benefit a virus that
has already entered the cell, it cannot be expected to persist for
a protracted period of time or to ensure that progeny released
from this infected cell will have a better chance of infecting addi-
tional host cells. In order to properly synthesize their proteins,
viruses have to attenuate the UPR responses, which they are
indeed known to do using a plethora of diverse mechanisms
(reviewed in He, 2006; Schroder and Kaufman, 2006). Once ER
stress is resolved, the PERK-dependent pathway that facilitates
turnover of IFNAR1 will be suspended, disabling a described
general mechanism for impeding IFN signaling. Under these
conditions, viruses will have to resort to individual tricks to main-
tain a degree of virulence in the environment containing IFNa/b.
Such mechanisms (including prevention of microorganism-
associated pattern recognition, reduced synthesis and secretion
of IFN, inhibition of the activity of regulatory kinases, etc.) have
been indeed widely reported (reviewed in Katze et al., 2002).
These mechanisms are of obvious importance for viral replica-
tion and subsequent transmission; they contribute to the forces
that drive coevolution of the pathogen and the mammalian host.
However, from the practical point of view of the host, inter-
fering with a nonspecific yet important mechanism enabling
initial steps of infection would represent an attractive strategyInc.
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the development of these diseases toward an abortive course.
Based on data presented here, it is tempting to speculate that
inhibitors of PERK-dependent phosphorylation of IFNAR1 might
exhibit a potent antiviral activity. As type I IFN also plays an im-
portant immunomodulatory role (Tompkins, 1999), it is plausible
that such effects would be even more pronounced in vivo.
Ongoing generation of phospho-degron knockin animals and
the design of the molecular means to inhibit the ligand-indepen-
dent IFNAR1 phosphorylation are expected to gain an important
insight. Given that we did not observe direct phosphorylation of
IFNAR1 by PERK (data not shown), future studies aimed at
understanding how exactly viruses and UPR mediate phosphor-
ylation-dependent ubiquitination and degradation of IFNAR1 are
warranted.
Additional incentive to proceed with further delineation of the
mechanisms that confer ligand-independent IFNAR1 degrada-
tion is the fact that type I IFNs are widely used in treatment of
patients with chronic viral infections (e.g., hepatitis C), multiple
sclerosis, and some malignancies. Whereas in cancer patients,
the rationale for combining IFN with other antitumor agents
that cause UPR (for example, proteasome inhibitors [Fribley
et al., 2004; Nawrocki et al., 2005; Obeng et al., 2006]) might
be re-evaluated, design of the means that would impede
HCV-mediated ER stress and ensuing degradation of IFNAR1
(e.g., inhibitors of PERK-dependent pathways) is expected to
benefit the patients whose therapeutic regiment includes IFNa.
EXPERIMENTAL PROCEDURES
Plasmids and Reagents
Vectors for bacterial expression of GST-ctIFNAR1 and mammalian expression
of human and mouse FLAG-IFNAR1 were described previously (Kumar et al.,
2004, 2007b, 2003); other plasmids were generous gifts from J. Darnell (FLAG-
STAT1), R. Bartenschlager (HCV constructs), and K.U.Wagner (Cre). All shRNA
constructs used were based on pLKO.1. The specific hairpin sequences are
outlined in the Supplemental Data. Recombinant human IFNa2 was purchased
from Roche Diagnostics. Recombinant human and mouse IFNg and mouse
IFNb were purchased from PBL. TG, cycloheximide, and methylamine HCl
were purchased from Sigma.
Cell Culture and Virus
All cell lines were maintained in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% (v/v) fetal bovine serum (Hyclone) and various selec-
tion antibiotics when indicated. To acutely delete PERK in MEFs, MEFs
harboring PERKfl/fl were infected with control retrovirus or retrovirus express-
ing Cre. The transduced cells were selected by puromycin for 72 hr. The
surviving clones were pooled and used for further analysis. IFNAR1-null
MEFs, reconstituted with pBABE-puro-based retroviral vector encoding
FLAG-tagged mIFNAR1WT and mIFNAR1S526A (Kumar et al., 2003), were
generated and cultured in the presence of 4 mg/ml of puromycin.. Huh7-deriv-
ative cells introduced with a complete HCV genome or a subgenomic genome
were described in details in Luquin et al., 2007 and were cultured in the pres-
ence of 500 mg/ml of G418.
Mouse ES clones harboring a S526A mutation were obtained by homolo-
gous recombination. The targeting vector containing this mutation
(Figure 3A) was introduced via electroporation into the C57/BL6 ES cells.
The cells were subjected to neomycin selection, and DNA samples from
survived clones were analyzed by Southern blotting, using the indicated
probes to identify the homologous recombinants. For experiments, ES cells
were differentiated into embryonic bodies using a previously established
protocol reported elsewhere (Maatman et al., 2003). The embryonic bodies
were trypsinized and plated in gelatinized plates using IMDM containingCel10% FBS. VSV (Indiana serotype, a gift from R. Harty) was propagated in
HeLa cells.
Transfections and Lentiviral Vector-Mediated Gene Knockdown
Transfection of 293T cells and KR-2 cells (clone of cells harboring catalytically
inactive Tyk2) using LIPOfectamine Plus and of Huh7-derivatives using LIPO-
fecatimine-2000 (Invitrogen) was carried out according to manufacturer’s
recommendations. Replication-deficient lentiviral particles encoding shRNA
against GFP (shCON), hPERK and hIRE1a, or the empty virus control were
prepared via cotransfecting 293T cells with three other helper vectors as previ-
ously described (Dull et al., 1998). Viral supernatants were concentrated by
PEG8000 precipitation and used to infect 2fTGH and U5A lines in the presence
of 3 mg/ml of polybrene (Sigma). Cells were selected and maintained in the
presence of 1.5 mg/ml of puromycin.
Cell Treatment and Viral Infection
For examining the signaling event occurring after initiation of ER stress, cells
were treated with vehicle (DMSO) or TG (1 mM, unless otherwise indicated)
for 0.5–2 hr, as shown in the figure legends. Unless otherwise specified, cells
were inoculated with VSV at an initial MOI of 0.1–1.0 for 1 hr. After removing the
virus inoculum, cells were then fed with fresh medium. Cells were harvested at
different time points afterwards; most of the effects were observed when the
cells were uniformly infected and viral markers were at saturation. In some
experiments, virus-infected cells were pulsed with IFNs for 30 min and then
harvested.
To examine the antiviral effect of IFN in relation to the time of its addition,
20 IU/ml of IFN was either added overnight prior to VSV infection or was added
after the initial virus inoculation/removal. Culture supernatant was generally
harvested 20 hr after the initial inoculation for analysis of viral titer. VSV titer
determination was performed as described elsewhere (Sharma et al., 2003).
Immunotechniques
Antibodies against pSTAT1, p-eIF2a, p-b-catenin, b-catenin, IRE1a (Cell
Signaling), STAT1 (Cell Signaling), eIF2a (Biosources), hIFNAR1, PKR, c-Jun,
IkBa (Santa Cruz), mIFNAR1 (R&D Systems), FLAG tag, b-actin (Sigma) and
ubiquitin (clone FK2, Biomol), ISG15, and PERK (Rockland) were used for
immunoprecipitation and immunoblotting. Monoclonal antibody 23H12,
specific for VSV-M, was kindly provided by D.S. Lyles (Wake Forest University
School of Medicine; Winston-Salem, NC). Antibody against IFNAR1 phosphor-
ylated on Ser535 (in human receptor) or Ser526 (in murine receptor) were
described previously (Kumar et al., 2004). Cell lysis, immunoprecipitation,
and immunoblotting procedures were described earlier (Kumar et al., 2004).
Kinase assay with cell lysates and GST-ctIFNAR1 as a substrate was previ-
ously described (Liu et al., 2008).
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, Supple-
mental References, and 19 figures and can be found online at http://www.
cell.com/cellhostandmicrobe/supplemental/S1931-3128(08)00395-8.
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